По всем вопросам звоните:

+7 495 274-22-22

УДК: 616.89 DOI:10.33920/med-01-2402-03

Этиопатогенез психических расстройств при рассеянном склерозе: тревожных, психотических расстройств, изменений личности, химических аддикций, патологического аффекта

Зимина Полина Артуровна студент, Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В. Ломоносова», Факультет фундаментальной медицины, https://orcid.org/0000-0002-7289-7713
Губская Ксения Владимировна к.м.н., ассистент кафедры психиатрии, наркологии и психотерапии института последипломного образования, федеральное государственное бюджетное образовательное учреждение высшего образования «Ивановская государственная медицинская академия» Министерства здравоохранения Российской Федерации, г. Иваново, e-mail: dr.gubskaia@ya.ru, https://orcid.org/0009-0007-6952-2367
Синицына Людмила Владимировна к.м.н., заведующая неврологическим отделением, Городская клиническая больница № 3, г. Иваново, https://orcid.org/0009-0005-5792-7047
Малыгин Ярослав Владимирович д.м.н., профессор кафедры психиатрии, наркологии и психотерапии, НОИ клинической медицины им. Н.А. Семашко, «Российский университет медицины», Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В. Ломоносова», Факультет фундаментальной медицины, профессор, malygin-y@yandex.ru, http://orcid.org/0000-0003-4633-6872
Анатолий Александрович Ахпашев студент, Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В. Ломоносова», Факультет фундаментальной медицины, https://orcid.org/0009-0003-7509-1912

Рассеянный склероз, являясь инвалидизирующим заболеванием, связан с повышенным риском возникновения сопутствующих психических расстройств среди взрослых пациентов. Настоящий литературный обзор призван отразить общую картину коморбидности РС и спектра тревожных и психотических расстройств: распространённость, особенности клинических проявлений, факторы риска возникновения подобной синтропии. Объем литературных данных по заданной теме ограничивается кросс-секционными исследованиями и частными клиническими случаями, в то время как лонгитюдные исследования, позволяющие прогнозировать вероятность возникновения, течение и исход заболевания, лимитированы.

Литература:

1. MS Society. MS in the UK January 2016 (PDF). Available from: www.mssociety.org.uk/ms-resources/ms-uk. Accessed October 11, 2016.

2. Mackenzie I. S., Morant S.V., Bloomfield G.A., MacDonald T. M., O’Riordan J. Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry. 2014;85 (1):76–84.

3. Willumsen JS, Grytten N, Aarseth J, Myklebust TÅ, Myhr KM, Midgard R. Mortality and cause of death in multiple sclerosis in western Norway 1950–2021: a registry-based linkage study. J Neurol Neurosurg Psychiatry. 2022 Sep 12;93 (11):1154–61. [doi: 10.1136/ jnnp-2022-329169]

4. Chou I.J., Kuo C. F., Tanasescu R., Tench C.R., Tiley C.G., Constantinescu C. S., Whitehouse W.P. Comorbidity in multiple sclerosis: its temporal relationships with disease onset and dose effect on mortality. Eur J Neurol. 2020 Jan;27 (1):105–112. [doi: 10.1111/ ene.14040]

5. Huang Y.C., Chien W.C., Chung C.H., Chang H.A., Kao Y.C., Wan F.J., Huang S.H., Chung R.J., Wang R. S., Wang B. L., Tzeng N. S., Sun C.A. Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population. Neuropsychiatr Dis Treat. 2021 Feb 22;17:587–604. [doi: 10.2147/NDT.S268360]

6. Prakash R.S., Schirda B., Valentine T.R., Crotty M., Nicholas J.A. Emotion dysregulation in multiple sclerosis: Impact on symptoms of depression and anxiety. Mult Scler Relat Disord. 2019 Nov; 36:101399. [doi: 10.1016/j.msard.2019.101399]

7. Margoni M., Preziosa P., Rocca M.A., Filippi M.. Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis. Transl Psychiatry. 2023 Jul 19; 13 (1): 264. [doi: 10.1038/s41398-023-02555-7]

8. Zhang X., Song Y., Wei Z., Chen X., Zhuang X., Yi L. The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis. Front Neurosci. 2023 Apr 17; 17:1120541. [doi: 10.3389/fnins.2023.1120541]

9. Butler E., Thomas R., Carolan A., Silber E., Chalder T. ‘It’s the unknown’ — understanding anxiety: from the perspective of people with multiple sclerosis. Psychology & health. 2019; 34 (3): 368–83.

10. Holland D., Schlüter D., Young C., et al. Use of coping strategies in multiple sclerosis: Association with demographic and diseaserelated characteristics. Multiple sclerosis and related disorders. 2019; 27: 214–22.

11. Paparrigopoulos T., Ferentinos P., Kouzoupis A., Koutsis G., Papadimi-triou G.N. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010; 22: 14–21.

12. Hanna M., Strober L.B. Anxiety and depression in multiple sclerosis (MS): antecedents, consequences, and differential impact on well-being and quality of life. Mult Scler Relat Disord. 2020; 44: 10.

13. Podda J., Uccelli M.M., Tacchino A., Pedullà L., Bragadin M.M., Battaglia M.A., Brichetto G., Ponzio M. Predictors of Mood Disorders in Parents With Multiple Sclerosis: The Role of Disability Level, Coping Techniques, and Perceived Social Support. Int J MS Care. 2022 Sep-Oct; 24 (5): 224–229. [doi: 10.7224/1537–2073.2021–101]

14. Gay M., Bungener C., Thomas S., et al. Anxiety, emotional processing and depression in people with multiple sclerosis. BMC Neurol 2017;17:43.

15. Marrie R.A., Reingold S., Cohen J., Stuve O., Trojano M., Sorensen P.S., et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015; 21: 305–317.

16. Bachut M., Szczegielniak A.,?wierzy K., Tarska M., Kubicka-B?czyk K., Sowa M., Gorczyca P. Prevalence of psychiatric disorders among patients with Multiple Sclerosis: a cross-sectional study. 2020; PREPRINT (Version 1) available at Research Square [https://doi. org/10.21203/rs.3.rs-24149/v1]

17. Inanc Y., Tugba K. Psychiatric Disorders in Multiple Sclerosis. Journal of Multiple Sclerosis Research. 2022;2:31–35. [10.4274/ jmsr.galenos.2022.2022-8-1]

18. Tinelli E., Francia A., Quartuccio E.M., Morreale M., Contessa G.M., Pascucci S., Sbardella E., Pozzilli C., Pantano P. Structural brain MR imaging changes associated with obsessive-compulsive disorder in patients with multiple sclerosis. AJNR Am J Neuroradiol. 2013;34:305–309.

19. Douzenis A., Michalopoulou P.G., Voumvourakis C., Typaldou M., Michopoulos I., Lykouras L. Obsessive-compulsive disorder associated with parietal white matter multiple sclerosis plaques. World J Biol Psychiatry. 2009;10:956–960.

20. Chalfant A.M., Bryant R.A., Fulcher G. Posttraumatic stress disorder following diagnosis of multiple sclerosis. J Trauma Stress. 2004 Oct;17 (5):423–8. [doi: 10.1023/B:JOTS.0000048955.65891.4c]

21. Counsell A., Hadjistavropoulos H.D., Kehler M.D., Asmundson G.J. G. Posttraumatic stress disorder symptoms in individuals with multiple sclerosis. Psychological Trauma: Theory, Research, Practice, and Policy. 2013;5 (5):448–452. [https://doi.org/10.1037/ a0029338]

22. Carletto S., Borghi M., Scavelli F., Francone D., Perucchini M.L., Cavallo M., Pagnini F., Bertolotto A., Oliva F., Ostacoli L. Prevalence of Posttraumatic Stress Disorder in Patients With Multiple Sclerosis. J Nerv Ment Dis. 2018 Feb;206 (2):149–151. [doi: 10.1097/ NMD.0000000000000780]

23. Leekoff M., Culpepper W., Jin S., Lee-Wilk T., Wallin M. Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study. Mult Scler. 2022 Jul;28 (8):1257–1266. [doi: 10.1177/13524585211058361]

24. Chalah M.A., Ayache S. S.. Psychiatric event in multiple sclerosis: could it be the tip of the iceberg? Braz J Psychiatry. 2017 OctDec;39 (4):365–368. [doi: 10.1590/1516-4446-2016-2105]

25. Hartoonian N., Terril A. L., Beier M. L., Turner A., Day MA., Alschuler K. Predictors of anxiety in multiple sclerosis. Rehabilitation Psychology. 2015;60 (1); 91–98. [doi: 10.1037/rep0000019]

26. Hillyer A., Sharma M., Kuurstra A., Rosehart H., Menon R., Morrow S.A. Association between limbic system lesions and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2023 Nov;79:105021. [doi: 10.1016/j.msard.2023.105021]

27. Lin A., Chen F., Liu F., Li Z., Liu Y., Lin S., Wang X., Zhu J. Regional gray matter at- rophy and neuropsychologcal problems in relapsing-remitting multiple sclerosis. Neural Regeneration Research. 2013;8:1958–1965.

28. Malygin V., Boyko A., Konovalova O., Pahtusova E., Dumbrova E., Tishina I., Malygin Y. Anxiety and depressive psychopathological characteristics of patients with multiple sclerosis at different stages of disease. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2019;119 (2):58. [doi:10.17116/jnevro20191192258] (In Russian)

29. Marrie R.A., Horwitz R. I., Cutter G., Tyry T., Volmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurologica Scandinavica. 2011;124:135–141.

30. Fahy A., Maguire R. Potentially modifiable associates of anxiety in people with multiple sclerosis: a systematic review. Disabil Rehabil. 2022 Dec;44 (26):8201–8212. [doi: 10.1080/09638288.2021.2022776]

31. Honarmand K., Feinstein A. Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler. 2009;15:1518–1524.

32. Kosmidis M.H., Giannakou M., Messinis L., Papathanasopoulos P. Psychotic features associated with multiple sclerosis. Int Rev Psychiatry. 2010;22:55–66.

33. Iakushina T. I., Belova Iu.A. Psychotic disorders in multiple sclerosis. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova. 2018;118 (8-2):110–115. (In Russian)

34. Camara-Lemarroy C.R., Ibarra-Yruegas B. E., Rodriguez-Gutierrez R., Berrios-Morales I., Ionete C., Riskind P. The varieties of psychosis in multiple sclerosis: A systematic review of cases. Mult Scler Relat Disord. 2017 Feb;12:9–14. [doi: 10.1016/j.msard.2016.12.012]

35. Robinson N., Bergen S. E. Environmental Risk Factors for Schizophrenia and Bipolar Disorder and Their Relationship to Genetic Risk: Current Knowledge and Future Directions. Front Genet. 2021 Jun 28;12:686666. [doi: 10.3389/fgene.2021.686666]

36. Andreassen O., Harbo H., Wang Y., ThompsonW.K., Schork A.J., Mattingsdal M., Zuber V., Bettella F., Ripke S., Kelsoe J. R., Kendler K. S., O’Donovan M.C., Sklar P. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: Differential involvement of immune-related gene loci. Molecular Psychiatry. 2015;20:207–214.

37. Picchioni M., Toulopoulou T. Genetic determinants of the vulnerability to psychosis: Findings from twin studies. In: Fusar-Poli P, Borgwardt SJ, McGuir P (eds), Vulnerability to Psychosis: From Neurosciences to Psychopathology. 2012; Psychology Press 2013, p. 41.

38. Jeppesen R., Benros M. E. Autoimmune Diseases and Psychotic Disorders. Front Psychiatry. 2019 Mar 20;10:131. [doi: 10.3389/ fpsyt.2019.00131]

39. Vesic K., Gavrilovic A., Mijailović N.R., Borovcanin MM. Neuroimmune, clinical and treatment challenges in multiple sclerosisrelated psychoses. World J Psychiatry. 2023 Apr 19;13 (4):161–170. [doi: 10.5498/wjp.v13.i4.161]

40. Sabe M., Sentissi O. Psychotic symptoms prior or concomitant to diagnosis of multiple sclerosis: a systematic review of case reports and case series. Int J Psychiatry Clin Pract. 2022 Sep;26 (3):287–293. [doi: 10.1080/13651501.2021.1973506]

41. Adams K., Cimino J.E., Arnold R.M., Anderson W.G. Why should I talk about emotion? Communication patterns associated with physician discussion of patient expressions of negative emotion in hospital admission encounters. Patient Educ Couns. 2012;89:44–50.

42. Silveira C., Guedes R., Maia D., Curral R., Coelho R. Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art. Psychiatry Investig. 2019 Dec;16 (12):877–888. [doi: 10.30773/pi.2019.0106]

43. Goeb J. L., Cailleau A., Laine P., Etcharry-Bouyx F., Maugin D., Duverger P., et al. Acute delirium, delusion and depression during INF-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol. 2003;26:5–7.

44. Ramos J.A., Costa A.M. 1457 — Multiple Sclerosis, Psychosis And The Use Of Interferon Beta 1a: a Rare Clinical Case. European Psychiatry. 2013;28 (S1):1–1. [doi:10.1016/S0924–9338 (13) 76486–1]

45. Smith J.R., Robinson D.M. A Neuropsychiatric presentation of Multiple Sclerosis. American Journal of Psychiatry Residents’ Journal. 2018 Nov;13 (11):6–8.

46. Harel Y., Barak Y., Achiron A. Dysregulation of affect in multiple sclerosis: new phenomenological approach. Psychiatry Clin Neurosci. 2007;61:94–98.

47. Nazari K.M., Samouei R., Sarrafzadeh S., Tamannaeifar S., Ghaebi N., Behrouzi R. Relation between personality disorders and characteristics of multiple sclerosis patients and their parents. J Educ Health Promot. 2018 Aug 2;7:106. [doi: 10.4103/jehp.jehp_185_17]

48. Feinstein A. Neuropsychiatric syndromes associated with multiple sclerosis. J Neurol 2007;254 (Suppl 2):ii73-ii76.

49. Mirzaei M., Jaryani N., Masafi S., Afsaraski S., Dolatshahi B., Rezaei O. Identifying the personality patterns in patients with multiple sclerosis (MS). International Journal of Collaborative Research on Internal Medicine and Public Health. 2012;4:1901–1911.

50. Jacot de Alcântara I., Voruz P., Allali G., Fragnoli C., Antoniou M.P., Lalive P.H., Péron J.A. Personality as a Predictor of Disability in Multiple Sclerosis. Arch Clin Neuropsychol. 2023 Jul 25;38 (5):657–666. [doi: 10.1093/arclin/acad010]

51. Luca M., Chisari C.G., Zanghì A., Patti F. Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges. International Journal of Environmental Research and Public Health. 2021;18 (11):5588. [https://doi.org/10.3390/ijerph181155]

52. Turner A.P., Arewasikporn A., Hawkins E.J., Suri P., Burns S.P., Leipertz S. L., Haselkorn J.K. Risk Factors for Chronic Prescription Opioid Use in Multiple Sclerosis. Arch Phys Med Rehabil. 2023 Nov;104 (11):1850–1856. [doi: 10.1016/j.apmr.2023.04.012]

53. Ayoobi F., Bidaki R., Shamsizadeh A., Moghadam-Ahmadi A., Amiri H. Impact of opium dependency on clinical and neuropsychological indices of multiple sclerosis patients. Neurol Sci. 2019 Dec;40 (12):2501–2507. [doi: 10.1007/s10072-019-03971-8]

54. Lechtenberg R. Multiple Sclerosis Fact Book. 2nd Edition. Philadelphia: FA Davis; 1995.

55. Chong M. S., Wolff K., Wise K., Tanton C., Winstock A., Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler. 2006;12:646–651.

56. Feinstein A., Meza C., Stefan C., Staines R.W. Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis. Brain. 2019 Sep 1;142 (9):2800–2812. [doi: 10.1093/brain/awz213]

57. Feinstein A., Meza C., Stefan C., Staines W.R. Discontinuing cannabis improves depression in people with multiple sclerosis: A short report. Mult Scler. 2021 Apr;27 (4):636–639. [doi: 10.1177/1352458520934070]

58. Charcot J., Seigerson G. «Lectures 6 through 8,» in Lectures on the Diseases of the Nervous System. Delivered at La Salpetriere. Am J Med Sci. 1877; 148 (4):532–533. [doi:10.1097/00000441–187710000–00035]

59. Cottrell S., Wilson S. Original Papers: The affective symptomatology of disseminated sclerosis: a study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry. 1926; s1–7 (25):1–30. [doi:10.1136/jnnp. s1–7.25]

60. Iacovides A., Andreoulakis E. Bipolar disorder and resembling special psychopathological manifestations in multiple sclerosis: a review. Current Opinion in Psychiatry. 2011 Jul;24 (4):336–40. [doi: 10.1097/YCO.0b013e328347341d]

61. Hübers A., Kassubek J., Grön G., Gorges M., Aho-Oezhan H., Keller J., Horn H., Neugebauer H., Uttner I., Lulé D., Ludolph A.C. Pathological laughing and crying in amyotrophic lateral sclerosis is related to frontal cortex function. Journal of Neurology. 2016 Sep;263 (9):1788–95. [doi: 10.1007/s00415-016-8201-5]

62. Chwastiak L.A., Ehde D.M. Psychiatric issues in multiple sclerosis. The Psychiatric clinics of North America. 2007;30:803–817.

63. Özer D., Ata E. E., Dikeç G., Demir S. The relationship between stress, anxiety, and depression levels and pseudobulbar affect in patients with multiple sclerosis. Contemp Nurse. 2022 Aug;58 (4):317–329. [doi: 10.1080/10376178.2022.2107037]

64. Fitzgerald K.C., Salter A., Tyry T., Fox R.J., Cutter G., Marrie R.A. Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis. Neurol Clin Pract. 2018 Dec;8 (6):472–481. [doi: 10.1212/CPJ.0000000000000523]

1. MS Society. MS in the UK January 2016 (PDF). Available from: www.mssociety.org.uk/ms-resources/ms-uk. Accessed October 11, 2016.

2. Mackenzie I. S., Morant S.V., Bloomfield G.A., MacDonald T. M., O’Riordan J. Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry. 2014;85 (1):76–84.

3. Willumsen JS, Grytten N, Aarseth J, Myklebust TÅ, Myhr KM, Midgard R. Mortality and cause of death in multiple sclerosis in western Norway 1950–2021: a registry-based linkage study. J Neurol Neurosurg Psychiatry. 2022 Sep 12;93 (11):1154–61. [doi: 10.1136/jnnp-2022-329169]

4. Chou I.J., Kuo C. F., Tanasescu R., Tench C. R., Tiley C.G., Constantinescu C. S., Whitehouse W. P. Comorbidity in multiple sclerosis: its temporal relationships with disease onset and dose effect on mortality. Eur J Neurol. 2020 Jan;27 (1):105–112. [doi: 10.1111/ene.14040]

5. Huang Y.C., Chien W.C., Chung C.H., Chang H.A., Kao Y.C., Wan F.J., Huang S.H., Chung R.J., Wang R. S., Wang B. L., Tzeng N. S., Sun C.A. Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population. Neuropsychiatr Dis Treat. 2021 Feb 22;17:587–604. [doi: 10.2147/NDT.S268360]

6. Prakash R. S., Schirda B., Valentine T. R., Crotty M., Nicholas J.A. Emotion dysregulation in multiple sclerosis: Impact on symptoms of depression and anxiety. Mult Scler Relat Disord. 2019 Nov; 36:101399. [doi: 10.1016/j.msard.2019.101399]

7. Margoni M., Preziosa P., Rocca M.A., Filippi M.. Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis. Transl Psychiatry. 2023 Jul 19; 13 (1): 264. [doi: 10.1038/s41398-023-02555-7]

8. Zhang X., Song Y., Wei Z., Chen X., Zhuang X., Yi L. The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis. Front Neurosci. 2023 Apr 17; 17:1120541. [doi: 10.3389/fnins.2023.1120541]

9. Butler E., Thomas R., Carolan A., Silber E., Chalder T. ‘It’s the unknown’ — understanding anxiety: from the perspective of people with multiple sclerosis. Psychology & health. 2019; 34 (3): 368–83.

10. Holland D., Schlüter D., Young C., et al. Use of coping strategies in multiple sclerosis: Association with demographic and disease-related characteristics. Multiple sclerosis and related disorders. 2019; 27: 214–22.

11. Paparrigopoulos T., Ferentinos P., Kouzoupis A., Koutsis G., Papadimi-triou G.N. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010; 22: 14–21.

12. Hanna M., Strober L.B. Anxiety and depression in multiple sclerosis (MS): antecedents, consequences, and differential impact on well-being and quality of life. Mult Scler Relat Disord. 2020; 44: 10.

13. Podda J., Uccelli M. M., Tacchino A., Pedullà L., Bragadin M. M., Battaglia M.A., Brichetto G., Ponzio M. Predictors of Mood Disorders in Parents With Multiple Sclerosis: The Role of Disability Level, Coping Techniques, and Perceived Social Support. Int J MS Care. 2022 Sep-Oct; 24 (5): 224–229. [doi: 10.7224/1537–2073.2021–101]

14. Gay M., Bungener C., Thomas S., et al. Anxiety, emotional processing and depression in people with multiple sclerosis. BMC Neurol 2017;17:43.

15. Marrie R.A., Reingold S., Cohen J., Stuve O., Trojano M., Sorensen P. S., et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015; 21: 305–317.

16. Bachut M., Szczegielniak A.,?wierzy K., Tarska M., Kubicka-B?czyk K., Sowa M., Gorczyca P. Prevalence of psychiatric disorders among patients with Multiple Sclerosis: a cross-sectional study. 2020; PREPRINT (Version 1) available at Research Square [https:// doi.org/10.21203/rs.3.rs-24149/v1]

17. Inanc Y., Tugba K. Psychiatric Disorders in Multiple Sclerosis. Journal of Multiple Sclerosis Research. 2022;2:31–35. [10.4274/jmsr.galenos.2022.2022-8-1]

18. Tinelli E., Francia A., Quartuccio E.M., Morreale M., Contessa G.M., Pascucci S., Sbardella E., Pozzilli C., Pantano P. Structural brain MR imaging changes associated with obsessive-compulsive disorder in patients with multiple sclerosis. AJNR Am J Neuroradiol. 2013;34:305–309.

19. Douzenis A., Michalopoulou P.G., Voumvourakis C., Typaldou M., Michopoulos I., Lykouras L. Obsessive-compulsive disorder associated with parietal white matter multiple sclerosis plaques. World J Biol Psychiatry. 2009;10:956–960.

20. Chalfant A.M., Bryant R.A., Fulcher G. Posttraumatic stress disorder following diagnosis of multiple sclerosis. J Trauma Stress. 2004 Oct;17 (5):423–8. [doi: 10.1023/B:JOTS.0000048955.65891.4c]

21. Counsell A., Hadjistavropoulos H.D., Kehler M.D., Asmundson G.J. G. Posttraumatic stress disorder symptoms in individuals with multiple sclerosis. Psychological Trauma: Theory, Research, Practice, and Policy. 2013;5 (5):448–452. [https://doi.org/10.1037/a0029338]

22. Carletto S., Borghi M., Scavelli F., Francone D., Perucchini M. L., Cavallo M., Pagnini F., Bertolotto A., Oliva F., Ostacoli L. Prevalence of Posttraumatic Stress Disorder in Patients With Multiple Sclerosis. J Nerv Ment Dis. 2018 Feb;206 (2):149–151. [doi: 10.1097/NMD.0000000000000780]

23. Leekoff M., Culpepper W., Jin S., Lee-Wilk T., Wallin M. Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study. Mult Scler. 2022 Jul;28 (8):1257–1266. [doi: 10.1177/13524585211058361]

24. Chalah M.A., Ayache S. S.. Psychiatric event in multiple sclerosis: could it be the tip of the iceberg? Braz J Psychiatry. 2017 OctDec;39 (4):365–368. [doi: 10.1590/1516-4446-2016-2105]

25. Hartoonian N., Terril A. L., Beier M. L., Turner A., Day MA., Alschuler K. Predictors of anxiety in multiple sclerosis. Rehabilitation Psychology. 2015;60 (1); 91–98. [doi: 10.1037/rep0000019]

26. Hillyer A., Sharma M., Kuurstra A., Rosehart H., Menon R., Morrow S.A. Association between limbic system lesions and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2023 Nov;79:105021. [doi: 10.1016/j.msard.2023.105021]

27. Lin A., Chen F., Liu F., Li Z., Liu Y., Lin S., Wang X., Zhu J. Regional gray matter at- rophy and neuropsychologcal problems in relapsing-remitting multiple sclerosis. Neural Regeneration Research. 2013;8:1958–1965.

28. Malygin V. L., Boiko A.N., Konovalova O. E., Iskandirova A. S., Dumbrova E.V., Boiko O.V., Malygin Ia.V. Vliianie psikhopatologicheskikh faktorov i osobennostei lichnosti na rezultaty issledovaniia kachestva zhizni bolnykh rasseiannym sklerozom [Anxiety and depressive psychopathological characteristics of patients with multiple sclerosis at different stages of disease]. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova [S. S. Korsakov Journal of Neurology and Psychiatry]. 2019;119 (2):58. [doi:10.17116/jnevro20191192258] (In Russ.)

29. Marrie R.A., Horwitz R. I., Cutter G., Tyry T., Volmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurologica Scandinavica. 2011;124:135–141.

30. Fahy A., Maguire R. Potentially modifiable associates of anxiety in people with multiple sclerosis: a systematic review. Disabil Rehabil. 2022 Dec;44 (26):8201–8212. [doi: 10.1080/09638288.2021.2022776]

31. Honarmand K., Feinstein A. Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler. 2009;15:1518–1524.

32. Kosmidis M.H., Giannakou M., Messinis L., Papathanasopoulos P. Psychotic features associated with multiple sclerosis. Int Rev Psychiatry. 2010;22:55–66.

33. Iakushina T. I., Belova Iu.A. Psikhoticheskie narusheniia pri rasseiannom skleroze [Psychotic disorders in multiple sclerosis]. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova [S. S. Korsakov Journal of Neurology and Psychiatry]. 2018;118 (8-2):110–115. (In Russ.)

34. Camara-Lemarroy C.R., Ibarra-Yruegas B. E., Rodriguez-Gutierrez R., Berrios-Morales I., Ionete C., Riskind P. The varieties of psychosis in multiple sclerosis: A systematic review of cases. Mult Scler Relat Disord. 2017 Feb;12:9–14. [doi: 10.1016/j.msard.2016.12.012]

35. Robinson N., Bergen S. E. Environmental Risk Factors for Schizophrenia and Bipolar Disorder and Their Relationship to Genetic Risk: Current Knowledge and Future Directions. Front Genet. 2021 Jun 28;12:686666. [doi: 10.3389/fgene.2021.686666]

36. Andreassen O., Harbo H., Wang Y., ThompsonW.K., Schork A.J., Mattingsdal M., Zuber V., Bettella F., Ripke S., Kelsoe J.R., Kendler K.S., O'Donovan M.C., Sklar P. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: Differential involvement of immune-related gene loci. Molecular Psychiatry. 2015;20:207–214.

37. Picchioni M., Toulopoulou T. Genetic determinants of the vulnerability to psychosis: Findings from twin studies. In: Fusar-Poli P, Borgwardt SJ, McGuir P (eds), Vulnerability to Psychosis: From Neurosciences to Psychopathology. 2012; Psychology Press 2013, p. 41.

38. Jeppesen R., Benros M.E. Autoimmune Diseases and Psychotic Disorders. Front Psychiatry. 2019 Mar 20;10:131. [doi: 10.3389/fpsyt.2019.00131]

39. Vesic K., Gavrilovic A., Mijailović N.R., Borovcanin MM. Neuroimmune, clinical and treatment challenges in multiple sclerosis-related psychoses. World J Psychiatry. 2023 Apr 19;13 (4):161–170. [doi: 10.5498/wjp.v13.i4.161]

40. Sabe M., Sentissi O. Psychotic symptoms prior or concomitant to diagnosis of multiple sclerosis: a systematic review of case reports and case series. Int J Psychiatry Clin Pract. 2022 Sep;26 (3):287–293. [doi: 10.1080/13651501.2021.1973506]

41. Adams K., Cimino J.E., Arnold R.M., Anderson W.G. Why should I talk about emotion? Communication patterns associated with physician discussion of patient expressions of negative emotion in hospital admission encounters. Patient Educ Couns. 2012;89:44–50.

42. Silveira C., Guedes R., Maia D., Curral R., Coelho R. Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art. Psychiatry Investig. 2019 Dec;16 (12):877–888. [doi: 10.30773/pi.2019.0106]

43. Goeb J. L., Cailleau A., Laine P., Etcharry-Bouyx F., Maugin D., Duverger P., et al. Acute delirium, delusion and depression during INF-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol. 2003;26:5–7.

44. Ramos J.A., Costa A.M. 1457 — Multiple Sclerosis, Psychosis And The Use Of Interferon Beta 1a: a Rare Clinical Case. European Psychiatry. 2013;28 (S1):1–1. [doi:10.1016/S0924–9338 (13) 76486–1]

45. Smith J.R., Robinson D.M. A Neuropsychiatric presentation of Multiple Sclerosis. American Journal of Psychiatry Residents' Journal. 2018 Nov;13 (11):6–8.

46. Harel Y., Barak Y., Achiron A. Dysregulation of affect in multiple sclerosis: new phenomenological approach. Psychiatry Clin Neurosci. 2007;61:94–98.

47. Nazari K. M., Samouei R., Sarrafzadeh S., Tamannaeifar S., Ghaebi N., Behrouzi R. Relation between personality disorders and characteristics of multiple sclerosis patients and their parents. J Educ Health Promot. 2018 Aug 2;7:106. [doi: 10.4103/jehp.jehp_185_17]

48. Feinstein A. Neuropsychiatric syndromes associated with multiple sclerosis. J Neurol 2007;254 (Suppl 2):ii73-ii76.

49. Mirzaei M., Jaryani N., Masafi S., Afsaraski S., Dolatshahi B., Rezaei O. Identifying the personality patterns in patients with multiple sclerosis (MS). International Journal of Collaborative Research on Internal Medicine and Public Health. 2012;4:1901–1911.

50. Jacot de Alcântara I., Voruz P., Allali G., Fragnoli C., Antoniou M.P., Lalive P.H., Péron J.A. Personality as a Predictor of Disability in Multiple Sclerosis. Arch Clin Neuropsychol. 2023 Jul 25;38 (5):657–666. [doi: 10.1093/arclin/acad010]

51. Luca M., Chisari C.G., Zanghì A., Patti F. Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges. International Journal of Environmental Research and Public Health. 2021;18 (11):5588. [https://doi.org/10.3390/ijerph181155]

52. Turner A.P., Arewasikporn A., Hawkins E.J., Suri P., Burns S.P., Leipertz S. L., Haselkorn J.K. Risk Factors for Chronic Prescription Opioid Use in Multiple Sclerosis. Arch Phys Med Rehabil. 2023 Nov;104 (11):1850–1856. [doi: 10.1016/j.apmr.2023.04.012]

53. Ayoobi F., Bidaki R., Shamsizadeh A., Moghadam-Ahmadi A., Amiri H. Impact of opium dependency on clinical and neuropsychological indices of multiple sclerosis patients. Neurol Sci. 2019 Dec;40 (12):2501–2507. [doi: 10.1007/s10072-019-03971-8]

54. Lechtenberg R. Multiple Sclerosis Fact Book. 2nd Edition. Philadelphia: FA Davis; 1995.

55. Chong M. S., Wolff K., Wise K., Tanton C., Winstock A., Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler. 2006;12:646–651.

56. Feinstein A., Meza C., Stefan C., Staines R.W. Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis. Brain. 2019 Sep 1;142 (9):2800–2812. [doi: 10.1093/brain/awz213]

57. Feinstein A., Meza C., Stefan C., Staines W.R. Discontinuing cannabis improves depression in people with multiple sclerosis: A short report. Mult Scler. 2021 Apr;27 (4):636–639. [doi: 10.1177/1352458520934070]

58. Charcot J., Seigerson G. «Lectures 6 through 8,» in Lectures on the Diseases of the Nervous System. Delivered at La Salpetriere. Am J Med Sci. 1877; 148 (4):532–533. [doi:10.1097/00000441–187710000–00035]

59. Cottrell S., Wilson S. Original Papers: The affective symptomatology of disseminated sclerosis: a study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry. 1926; s1–7 (25):1–30. [doi:10.1136/jnnp. s1–7.25]

60. Iacovides A., Andreoulakis E. Bipolar disorder and resembling special psychopathological manifestations in multiple sclerosis: a review. Current Opinion in Psychiatry. 2011 Jul;24 (4):336–40. [doi: 10.1097/YCO.0b013e328347341d]

61. Hübers A., Kassubek J., Grön G., Gorges M., Aho-Oezhan H., Keller J., Horn H., Neugebauer H., Uttner I., Lulé D., Ludolph A. C. Pathological laughing and crying in amyotrophic lateral sclerosis is related to frontal cortex function. Journal of Neurology. 2016 Sep;263 (9):1788–95. [doi: 10.1007/s00415-016-8201-5]

62. Chwastiak L.A., Ehde D.M. Psychiatric issues in multiple sclerosis. The Psychiatric clinics of North America. 2007;30:803–817.

63. Özer D., Ata E. E., Dikeç G., Demir S. The relationship between stress, anxiety, and depression levels and pseudobulbar affect in patients with multiple sclerosis. Contemp Nurse. 2022 Aug;58 (4):317–329. [doi: 10.1080/10376178.2022.2107037]

64. Fitzgerald K.C., Salter A., Tyry T., Fox R.J., Cutter G., Marrie R.A. Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis. Neurol Clin Pract. 2018 Dec;8 (6):472–481. [doi: 10.1212/CPJ.0000000000000523]

Рассеянный склероз (РС) — аутоиммунное нейродегенеративное заболевание с хроническим прогредиентным течением, занимает одну из ведущих позиций среди аутоиммунных заболеваний, приводящих к инвалидизации молодого населения [1,2]. В ретроспективном когортном исследовании, основанном на данных о причинах смерти пациентов с установленным диагнозом РС, собранных в период с 1950 по 2021 года из Норвежского реестра и биобанка, а также Норвежского реестра причин смерти, 49 % пациентов умерли непосредственно от РС и его осложнений. По сравнению с общей популяцией, средняя ожидаемая продолжительность жизни больных РС была на 8,8 лет короче, а с момента начала заболевания пациенты прожили на 14,6 лет меньше, чем население в целом [3]. Наличие сопутствующих заболеваний до постановки диагноза РС увеличивает общую смертность среди людей этой группы [4]. Это заболевание связано с повышенным риском развития психических расстройств среди взрослых [5]. РС ассоциирован с широким спектром психических расстройств, включая различные виды расстройств настроения, аффекта и поведения наряду с когнитивными нарушениями, при этом наиболее характерными для данного заболевания являются расстройства невротического регистра, в частности аффективные и тревожные расстройства [6]. Несмотря на разнообразие сопутствующих психических патологий, большинство из них зачастую упускается из виду, особенно на ранних этапах диагностики и лечения РС, что существенно влияет на функциональность, качество жизни пациентов, клиническое течение основного заболевания [7].

Целью настоящего обзора является рассмотрение психических расстройств, коморбидных РС, с акцентом внимания на важности мультидисциплинарного подхода и ранней диагностики в работе с подобными пациентами.

Согласно результатам метаанализа, уровень тревожности у пациентов с РС в значительной степени связан с возрастом, полом, совместным проживанием, предшествующим психиатрическим анамнезом, депрессией, соблюдением режима приема лекарств, рецидивирующе-ремиттирующим течением и исходным уровнем EDSS (Expanded Disability Status Scale, расширенная шкала статуса инвалидности) [8].

Для Цитирования:
Зимина Полина Артуровна, Губская Ксения Владимировна, Синицына Людмила Владимировна, Малыгин Ярослав Владимирович, Анатолий Александрович Ахпашев, Этиопатогенез психических расстройств при рассеянном склерозе: тревожных, психотических расстройств, изменений личности, химических аддикций, патологического аффекта. Вестник неврологии, психиатрии и нейрохирургии. 2024;2.
Полная версия статьи доступна подписчикам журнала
Язык статьи:
Действия с выбранными: